Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John C Bell

Showing results (151-160 of 199) with videos related to

Pageof 20
Sort By:
Journal for Immunotherapy of Cancer|January 22, 2026
Oncolytic vaccinia virus encoding constitutively active EPAC remodels the tumor microenvironment to enhance therapeutic efficacy with chemotherapy and surgeryStephen Boulton, Siddharth Singh, Bailey Organ, et al.
Nature Biotechnology|January 28, 2014
Smac mimetics and innate immune stimuli synergize to promote tumor deathShawn T Beug, Vera A Tang, Eric C LaCasse, et al.
Frontiers in Immunology|January 7, 2025
Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironmentVictoria A Jennings, Reah Rumbold-Hall, Gemma Migneco, et al.
Frontiers in Immunology|May 7, 2025
Corrigendum: Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironmentVictoria A Jennings, Reah Rumbold-Hall, Gemma Migneco, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 23, 2014
Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patientsTimothy P Cripe, Minhtran C Ngo, James I Geller, et al.
Journal of Cancer Research and Clinical Oncology|February 8, 2021
Personalized oncology and BRAF<sup>K601N</sup> melanoma: model development, drug discovery, and clinical correlationBrian A Keller, Brian J Laight, Oliver Varette, et al.
Cancer Research|October 24, 2012
Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cellsLee-Hwa Tai, Christiano Tanese de Souza, Simon Bélanger, et al.
Oncoimmunology|February 6, 2018
Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cellsTiphaine Delaunay, Mathilde Violland, Nicolas Boisgerault, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 3, 2011
Targeting tumor vasculature with an oncolytic virusCaroline J Breitbach, Naomi S De Silva, Theresa J Falls, et al.
Cancer Immunology Research|February 5, 2017
NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular VaccineAlmohanad A Alkayyal, Lee-Hwa Tai, Michael A Kennedy, et al.
Pageof 20

Showing results (151-160 of 199) with videos related to

Sort By:
Pageof 20
Journal for Immunotherapy of Cancer|January 22, 2026
Oncolytic vaccinia virus encoding constitutively active EPAC remodels the tumor microenvironment to enhance therapeutic efficacy with chemotherapy and surgeryStephen Boulton, Siddharth Singh, Bailey Organ, et al.
Nature Biotechnology|January 28, 2014
Smac mimetics and innate immune stimuli synergize to promote tumor deathShawn T Beug, Vera A Tang, Eric C LaCasse, et al.
Frontiers in Immunology|January 7, 2025
Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironmentVictoria A Jennings, Reah Rumbold-Hall, Gemma Migneco, et al.
Frontiers in Immunology|May 7, 2025
Corrigendum: Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironmentVictoria A Jennings, Reah Rumbold-Hall, Gemma Migneco, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 23, 2014
Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patientsTimothy P Cripe, Minhtran C Ngo, James I Geller, et al.
Journal of Cancer Research and Clinical Oncology|February 8, 2021
Personalized oncology and BRAF<sup>K601N</sup> melanoma: model development, drug discovery, and clinical correlationBrian A Keller, Brian J Laight, Oliver Varette, et al.
Cancer Research|October 24, 2012
Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cellsLee-Hwa Tai, Christiano Tanese de Souza, Simon Bélanger, et al.
Oncoimmunology|February 6, 2018
Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cellsTiphaine Delaunay, Mathilde Violland, Nicolas Boisgerault, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 3, 2011
Targeting tumor vasculature with an oncolytic virusCaroline J Breitbach, Naomi S De Silva, Theresa J Falls, et al.
Cancer Immunology Research|February 5, 2017
NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular VaccineAlmohanad A Alkayyal, Lee-Hwa Tai, Michael A Kennedy, et al.
Pageof 20